More specifically, CTLA-4 inhibitors enhance T-cell activation and promote an immune response against cancer cells by blocking the downregulation of immune responses, while PD-1/PD-L1 inhibitors allow T-cells to effectively attack cancer cells by blocking inhibitory interactions [12]. Here, CTLA4 is linked to cancer.